Methods and apparatus for a coated anchoring device and/or suture

Information

  • Patent Grant
  • 6689153
  • Patent Number
    6,689,153
  • Date Filed
    Friday, April 14, 2000
    24 years ago
  • Date Issued
    Tuesday, February 10, 2004
    20 years ago
Abstract
A coated/impregnated anchoring device and/or suture to prevent infection, deliver site specific drugs, and deliver human growth factors to the surgical site. The coatings can include anti-microbial agents to prevent or fight infection en route to and at the surgical site. The coatings can also include site specific drugs and/or human growth factors to fight infection, anesthetize tissue and/or bone en route and at the site, promote tissue regeneration, promote bone regeneration, and/or other desired medical processes.
Description




BACKGROUND OF THE INVENTION




1. Technical Field




The present invention generally relates to an anchoring device and/or suture and methods for its use. More particularly, the present invention relates to a coated anchoring device and/or suture and methods for its use.




2. Background Art and Technical Problems




In many surgical procedures requiring tissue to tissue, tissue to bone, and bone to bone fixation, anchoring devices are used in conjunction with a suture to secure the fixation site. For example, the anchoring device could be a screw to join tissue and/or bone, and the suture could be a type of stitch to bind the tissue and/or bone. The anchoring device and/or suture are susceptible to bacteria at every stage of insertion, from external to the body to internal to the tissue and/or bone. Although sterile conditions are desired at each stage of insertion, in practice, that is not always possible. For example, bacteria may originate outside the body and then use the anchoring device and/or suture as a vehicle for invading the body. Alternatively, bacteria may already exist inside the body and the anchoring device and/or suture may carry such bacteria to other areas continuing the infection process.




Sutures are available as both monofilaments and braided filaments with the filaments being comprised of a variety of polymers. The most common suture is a braided polyester. Wicking of bacteria in the suture can be a concern. Braided filaments possess interstices which are sites where bacteria can proliferate. As these bacterial colonies outgrow their homes, they begin to migrate further into the suture causing wicking. Thus, wicking is the process of bacteria infecting the suture and/or surrounding areas.




Sutures may be comprised of a variety of materials including, but not limited to, cellulose (cotton), protein-cellulose (silk), processed collagen (catgut), nylon, polypropylene, Aramid, polyglycolic acid, polyesters, polytetraflourethylene, steel, copper, silver, aluminum, various alloys, Mersilene™, Ticron™, Ethilon™, Prolene™, Ethiflex™, Polyglactin 910™, polyglycolide-lactide polymer (e.g., Vicryl™), polydioxanone (e.g., PDSm™), polyglecaprone 25 (e.g., Monocryl™), polyglyconate (e.g., Maxon™), and Ethibond™.




In other areas of medicine, known methods for reducing the potential for site infection include coatings on catheters or external fixation pins. One common anti-microbial used in these applications is metallic silver. For example, catheters coated with silver have already shown a reduction in infections of the urinary tract where they are used. In addition, antibiotic-impregnated cement has been used for postoperative infections. Fish et al., 49


Amer Jour Hosp Pharm


2469 (October 1992). For implant infections, an antibiotic-impregnated silicone rubber coating has been used to cover the implant devices. Rushton et al., 52


Jour of Neurology, Neurosurgery, and Psychiatry


223 (1989). Also, recombinant human Transforming Growth Factor-B1 adsorbed onto ceramic implants has been shown to improve bone cell repair. Overgaard et al., 43rd Annual Meeting of the Orthopedic Research Society (San Francisco, Calif., Feb. 9-13, 1997).




However, prior art devices and methods for reducing infection and expediting healing have mainly been directed to implants alone. Such devices and methods have failed to address other key elements introduced into the body during surgery, such as sutures and the problems associated with those elements, such as wicking. Accordingly, a method and apparatus which substantially reduce infection, expedite the healing process, and reduce the problems associated with wicking are needed.




SUMMARY OF THE INVENTION




The present invention includes a coated/impregnated anchoring device and/or suture which prevents infection, delivers site specific drugs, promotes tissue regeneration, and/or promotes bone regeneration in a variety of medical procedures. Coatings for the coated anchoring device and/or suture may include anti-microbial agents for fighting infection, site specific drugs for delivering drugs, or human growth factors for delivering growth factors. Thus, the present invention substantially reduces infection, expedites the healing process, and provides easier drug delivery.











BRIEF DESCRIPTION OF THE DRAWING FIGURES




The subject invention will hereinafter be described in the context of the appended drawing figures, wherein like numerals denote like elements, and:





FIG. 1

illustrates a prior art anchoring device;





FIG. 2

illustrates a prior art suture and a prior art braided polyester suture;





FIG. 3

illustrates a coated anchoring device of the present invention;





FIG. 4

illustrates an anchoring device and suture of the present invention inserted into a shoulder;





FIG. 5

illustrates a suture of the present invention; and





FIG. 6

illustrates a method of coating/impregnating an anchoring device and/or a suture in accordance with the present invention.











DETAILED DESCRIPTION




As discussed above, surgical anchoring devices are used in conjunction with surgical sutures to secure the fixation site. Since infection at the operative site and beyond can be a concern, the present invention combines an anti-microbial coating with the anchor and/or suture system commonly used by the surgeon. The present invention adds such a coating to the anchor and/or suture to prevent and reduce infection. The present invention can be used with any implantable surgical device where infection is a potential problem.




Other embodiments disclosed are site specific drug delivery coatings and human growth factor coatings using the existing anchors and/or sutures. For example, anchors and/or sutures comprising certain polymers have the ability to bond to drugs or human growth factors and subsequently release those substances to influence the area into which they are implanted.





FIG. 1

illustrates a prior art anchoring device


101


including spiral screw edges


103


, a suture hole


105


, and a tip


107


. As discussed above, anchoring device


101


can be used to attach tissue to tissue, tissue to bone, and/or bone to bone. In addition, anchoring device


101


may be used to attach prosthetic or other materials foreign to the body to tissue and/or bone in the body. The spiral screw edges


103


allow anchoring device


101


to be driven into the tissue and/or bone. In addition, tip


107


provides a sharp edge for the initial insertion or further penetration into the tissue and/or bone. Many metallic and polymeric anchors are available to the surgeon. For example, anchors can be made of any biocompatible material. Examples of biocompatible materials include at least one of stainless steel, titanium, animal bone, cadaveric bone, absorbables, polymers, and the like. Furthermore, examples of polymers include polyester, nylon, poly lactic acid (PLA), poly-L lactic acid (PLLA), poly glycolic acid (PGA), or other bioabsorbable polymer materials.





FIG. 2

illustrates a first prior art suture


201


and a second prior art suture


203


. First suture


201


shows a generic suture used to fix tissue and/or bone to tissue and/or bone. First suture


201


loops through anchoring device


01


of FIG.


1


through suture hole


105


to anchor the tissue and/or bone to tissue and/or bone. Likewise, first suture


201


can be used independently to join tissue and/or bone, as is commonly done in stitching.




First suture


201


and second suture


203


can be made of a variety of materials for a variety of uses. For example, second suture


203


is available as a plurality of monofilaments that are braided together where the monofilaments are comprised of a variety of polymers, the most common being braided polyester. The braided interstices


205


and


207


of a braided polyester second suture


203


show where bacteria can proliferate, as discussed above. Thus, wicking of bacteria in the suture can be a concern.





FIG. 3

illustrates the present invention embodied in an anchoring device


301


. A coating


303


covers anchoring device


301


either partially or completely depending on the desired use. As such, a predetermined portion of anchoring device


301


may be coated depending on the desired use. Additionally, anchoring device


301


may be impregnated by coating


303


. Coating


303


can be at least one of an anti-microbial agent, a site specific drug, human growth factors, and the like.




The anti-microbial agents prevent the anchoring device and/or a suture from carrying or transferring infection during insertion of the anchoring device into tissue and/or bone, or at subsequent levels of insertion. The anti-microbial agents create effective barriers to the proliferation of bacteria on or around the anchoring device and/or the suture. In addition, the present invention places effective barriers to the proliferation of bacteria within the suture itself using anti-microbial agents that can be coated, impregnated, and/or bonded to the suture. For example, suitable coatings include at least one of silver, Silicone Rubber Coating, Fibrin Glue, Polymethylmethacrylate (PMMA) Cement, Hydroxyapatite Cement, PMMA Beads, Antibiotic Spray, Biodegradable Collagens, Liposomes, Collagen scaffold, Poylactuc acid microcapsules, Poly-L-lactic Acid (PLLA) scaffold, Polyhydroxyethyl methacrylate (pHEMA), Polyvinylalcohol and gum arabica blend matrix, Xerogel discs using a sol-gel process, and the like. Such suitable coatings may include one or more antimicrobial agents, such as gentamycin, benzethonium chloride, acid antibiotics, penicillin, high-heparin content polyquaternary polyurethane elastomers, cephlosporins, penicillanic acids, vancomycin, neomycin, erythromycin, streptomycin, cycloserine, tetracycline, aureomycin, terramycin (oxtetracycline) gentamycin, or polymyxin B, and the like.




Site specific drugs can, for example, enhance tissue or bone regeneration, treat local infection, anesthetize an area, and/or treat a variety of problems. The present invention provides a vehicle for transferring such site specific drugs to the necessary area, such as tissue and/or bone. Alternatively, or in conjunction with the anti-microbial, such site specific drugs may be needed at different levels of insertion of the anchoring device and/or the suture. For example, site specific drugs include at least one of Tobramycin, Gentamicin, Cefazolin, Vancomycin, Cephalothin, Oxacillin-nafcillin, Ceftriaxone, Cefuroxime, Unspecified cephalosporin, Bacitracin, Erythromycin-colistin, Polymyxin B, and the like.




Human growth factors can also enhance tissue and/or bone regeneration or stimulate other desired processes in or around tissue and/or bone. Once again, the present invention provides a vehicle in which such human growth factors can be transferred to the necessary area. Alternatively, or in conjunction with the anti-microbial and/or the site specific drugs, such human growth factors may be needed at different levels of insertion of the anchoring device and/or the suture. For example, anchoring devices made of certain polymers have the capability to bond to drugs or human growth factors and subsequently release the drugs or factors into the necessary area. Examples of such human growth factors include at least one of human growth hormones, morphogenic proteins, Transforming Growth Factor 1, Recombinant Human TGF-1, Bone Morphogenetic Protein-1, Recombinant Human BMP-2, Osteogenic growth peptide, Recombinant Human Growth Hormone, Basic fibroblast Growth Factor, Hepatocyte Growth Factor, and the like.




Coating


303


may be placed on anchoring device


301


and/or a suture (not shown) using a number of different techniques. As discussed above in relation to anchoring device


301


, a predetermined portion of the suture may be coated based on the desired use. Any technique that leaves an effective residual on the anchoring device


301


and/or the suture is adequate. For example, possible techniques for applying the suitable coating to anchoring device


301


and/or the suture include at least one of plasma deposition, dipping, wiping, and the like. As long as an effective residual coats the anchoring device and/or the suture, it will be adequate. If the accompanying suture is covered with a metal, then it may be necessary to cover that part of the suture which contacts anchoring device


301


with the suitable coating. Covering the suture with the suitable coating would reduce the potential for galvanic reactions, electrolysis, reactions at the surface, or the like. A separate embodiment would be a suture which is only partially coated.




In addition, anchoring device


301


and/or the suture may be impregnated by coating


303


by any suitable method. For example, anchoring device


301


and/or the suture may be impregnated by coating


303


by compounding, which entraps coating


303


into the biocompatible material that anchoring device


301


and/or the suture are made of. By way of illustration, if anchoring device


301


and the suture are made of a polymer, then mechanical compounding will entrap coating


303


between the interstices of the matrix of the polymer material. Another example of impregnating coating


303


into anchoring device


301


and/or the suture is by chemically bonding coating


303


into the biocompatible material of anchoring device


301


and/or the suture. Thus, mechanically entrapping coating


303


or chemically bonding coating


303


into anchoring device


301


and/or the suture are two examples of methods by which anchoring device


301


and/or the suture may be impregnated by coating


303


. Of course, those skilled in the art will appreciate that various other methods of impregnation are available.





FIG. 4

illustrates how an anchoring device


407


may need to travel through several stages of insertion into a shoulder


401


. Shoulder


401


depicts anchoring device


407


with suture


405


traveling through surface tissue


402


, muscle and/or ligament


403


, and bone


409


. At each level of penetration, anchoring device


407


and suture


405


are susceptible to bacteria. A coating on anchoring device


407


and/or suture


405


, as discussed above, would prevent such bacteria from proliferating on surface tissue


402


, muscle and/or ligament


403


, and/or bone


409


. Alternatively, or in conjunction with preventing proliferation of bacteria, each level of penetration may require delivery of site specific drugs or human growth factors to the necessary area. The present invention which includes anchoring device


407


and/or suture


405


with a suitable coating could deliver such drugs or factors to the necessary area.




To further illustrate the present invention as applied to a suture


501


, refer to FIG.


5


. Suture


501


includes a braided section


503


, an interstice


505


, and an individual fiber


507


. In between several braided sections


503


, interstices


505


may become infected and cause wicking, as described above. Also, in between individual fibers


507


, bacteria and infection can cause wicking. A coating


509


, similar to coating


303


of

FIG. 3

, applied to a predetermined portion of suture


501


may reduce infection, expedite the healing process, and provide easier drug delivery. Coating


509


may be applied to braided section


503


, interstice


505


, and/or individual fiber


507


, and may either partially cover or entirely encapsulate braided section


503


, interstice


505


, and/or individual fiber


507


. In addition, braided section


503


, interstice


505


, and/or individual fiber


507


may be impregnated with coating


509


. Thus,

FIG. 5

illustrates one embodiment of the present invention as applied to suture


501


.




Referring now to

FIG. 6

, flowchart


601


of the present invention illustrates one method of coating/impregnating an anchoring device and/or a suture. In step


603


, an anchoring device and/or suture are coated with a suitable coating. Of course, as discussed above, step


603


may alternatively, or also involve impregnating the anchoring device and/or the suture with one or more of an anti-microbial, a site specific drug, or a human growth factor. The suitable coating controls infection in step


605


, delivers site specific drugs in step


607


, and/or delivers human growth factors in step


609


. As discussed above, controlling infection in step


605


may involve using at least one anti-microbial, delivering site specific drugs in step


607


may include at least one of enhancing tissue or bone regeneration, treating local infection, or anesthetizing an area, and delivering human growth factors in step


609


may enhance tissue or bone regeneration, or stimulate other desired processes.




Tissue and/or bone to tissue and/or bone fixation represents one use for the devices and methods embodied in the present invention. Risk of infection is one of the most critical elements in a surgical procedure. Addition of a barrier to infection and prophelactic methods adds an additional level of protection for the patient which can be effective at the implant site and is an improvement over related anchors and/or sutures. In addition, other embodiments of the present invention include coating (and/or impregnating) the anchoring device and/or suture with site specific drugs and/or human growth factors to promote tissue regeneration, bone regeneration, or other desired bodily processes.




Although the invention has been described herein with reference to the appended drawing figures, it will be appreciated that the scope of the invention is not so limited. Various modifications in the design and implementation of various components and method steps discussed herein may be made without departing from the spirit and scope of the invention, as set forth in the appended claims.



Claims
  • 1. A medical device comprising:a suture anchor; and a coating covering a predetermined portion of said suture anchor, wherein said coating includes at least one of an anti-microbial agent or a site specific drug, wherein said coating includes at least one of: a silver, a Silicone Rubber Coating, a Fibrin Glue, a Polymethylethacrylate (PMMA) Cement, a Hydroxyanatite Cement, a plurality of PMMA Beads, an Antibiotic Spray, a biodegradable Collagen, a Liposomes, a Collegen Scaffold, a Poylactuc acid microcapsule, a Poly-L-lactic Acid (PLLA) scoffold, a Polyhydroxyethyl methacrylate (pHEMA), a Polwvinylalcholo and a gum arabica blend matrix, or a plurality of Xerogel discs using a solgel process; and a gentamycin, a benzethonium chloride, an acid antibiotic, a penicillin, a high heparin content polyquaternary polyurethane elastomer, a cephiosporin, a penicillanic acid, a vancomycin, a neomycin, an erythromycin, a streptomycin, a cycloserine, a tetracycline, an aureomycin, a terramycin (oxtetracycline) gentamycin, or a polymyxin B.
  • 2. The device of claim 1 wherein said suture anchor comprises a biocompatible material.
  • 3. The device of claim 2 wherein said biocompatible material includes at least one of a stainless steel, a titanium, a polymer, a bone, or an absorbable.
  • 4. The device of claim 3 wherein said polymer includes at least one of a polyester, a nylon, a poly lactic acid (PLA), a poly-L lactic acid (PLLA), or a poly glycolic acid (PGA).
  • 5. The device of claim 1 further comprising a surgical suture.
  • 6. The device of claim 5 wherein said surgical suture comprises a biocompatible material including at least one of a polymer, a cellulose based (cotton), a protein-cellulose (silk), a processed collagen (catgut), a nylon, a polypropylene, an Aramid, a polyglycolic acid, a polyesters, a polytetraflourethylene, a steel, a copper, a silver, an aluminum, an alloy, a polyglycolide-lactide polymer, a polydioxanone, a polyglecaprone 25, or a polyglyconate.
  • 7. The device of claim 5 wherein a predetermined portion of said surgical suture is coated with at least one of a bactericide, a site specific drug, or a human growth factor.
  • 8. The device of claim 7 wherein said human growth factor includes at least one of a human growth hormone, a morphogenic protein, a Transforming Growth Factor 1, a Recombinant Human TGF-1, a Bone Morphogenetic Protein-1, a Recombinant Human BMP-2, an Osteogenic growth peptide, a Recombinant Human Growth Hormone, a Basic fibroblast Growth Factor, or a Hepatocyte Growth Factor.
  • 9. The device of claim 7 wherein said human growth factor includes at least one of a human growth hormone, a morphogenic protein, a Transforming Growth Factor 1 a Recombinant Human TGF-1, a Bone Morphogenetic Protein-1, a Recombinant Human BMP-2, an Osteogenic growth peptide, a Recombinant Human Growth Hormone, a Basic fibroblast Growth Factor, or a Hepatocyte Growth Factor.
  • 10. The device of claim 5 wherein said surgical suture is impregnated with at least one of an anti-microbial, a site specific drug, or a human growth factor.
  • 11. The device of claim 5 wherein said surgical suture comprises a biocompatible material and is coated with said coating.
  • 12. The device of claim 5 wherein said site specific drug includes at least one of a Tobramycin, a Gentamicin, Cefazolin, a Vancomycin, a Cephalothin, an Oxacillin-nafoillin, a Ceftriaxone, Cefuroxime, an Unspecified cephalosporin, a Bacitracin, an Erythromycin-colistin, or Polymyxin B.
  • 13. The device of claim 12 wherein said coating is impregnated into at least one of said suture anchor or said surgical suture.
  • 14. The device of claim 5 wherein said anti-microbial agent includes a gentamycin, a benzethonium chloride, an acid antibiotic, a penicillin, a high-heparin content polyquaternary polyurethane elastomer, a cephlosporin, a penicillanic acid, a vancomycin, a neomycin, an erythromycin, a streptomycin, a cycloserine, a tetracycline, an aureomycin, a terramycin (oxtetracycline) gentamycin, and a polymyxin B.
  • 15. The device of claim 14 wherein said coating is impregnated into at least one of said suture anchor or said surgical suture.
  • 16. The device of claim 1 wherein said site specific drug includes at least one of a Tobramycin, a Gentamicin, a Cefazolin, a Vancomycin, a Cephalothin, an Oxacillinnafcillin, a Ceftriaxone, a Cefuroxime, an Unspecified cephalosporin, a Bacitracin, an Erythromycin-colistin, or a Polymyxin B.
  • 17. The device of claim 1 wherein the coating is impregnated into the suture anchor.
  • 18. A method for coating a suture anchor comprising the steps of:coating said suture anchor with a suitable coating; and configuring said suitable coating to include at least one of controlling infection or delivering site specific drugs, wherein said suitable coating comprises at least one of: a silver, a Silicone Rubber Coating, a Fibrin Glue, a Polymethylmethacrylate (PMMA) Cement, a Hydroxyapatite Cement, a plurality of PMMA Beads, an Antibiotic Spray, a Biodegradable Collagen, a Liposomes, a Collagen scaffold, a Poylactuc acid microcansule, a Poly-L-lactic Acid (PLLA) scaffold, a Polyhydroxyethyl methacrylate (pHEMA), a Polyvinylalcohol and a gum arabica blend matrix, or a plurality of Xerogel discs using a sol-gel process; and a gentamycin, a benzethonium chloride, an acid antibiotic, a penicillin, a high-heparin content polyvuaternary polyurethane elastomer, a cephlosporin, a penicillanic acid, a vancomycin, a neomycin, an erytbromycin, a streptomycin, a cycloserine, a tetracycline, an aureomycin, a terramycin (oxtetracycline) gentamycin, or polymyxin B.
  • 19. The method of claim 18 further comprising the step of coating a suture with said suitable coating.
  • 20. The method of claim 19 wherein said suture comprises a biocompatible material including at least one of a polymer, a cellulose based (cotton), a protein-cellulose (silk), a processed collagen (catgut), a nylon, a polypropylene, an Aramid, a polyglycolic acid, a polyesters, a polytetraflourethylene, a steel, a copper, a silver, an aluminum, an alloy, a polyglycolide-lactide polymer, a polydioxanone, a polyglecaprone 25, or a polyglyconate.
  • 21. The method of claim 19, wherein said suture comprises braided filaments having interstices and said suitable coating covers a predetermined portion of said interstices of said suture.
  • 22. The method of claim 21 further comprising impregnating said suitable coating into said suture.
  • 23. The method of claim 19 further comprising impregnating said suitable coating into at least one of said suture anchor or said suture.
  • 24. The method of claim 19 wherein said suitable coating comprises a human growth factor including a human growth hormone, a morphogenic protein, a Transforming Growth Factor 1, a Recombinant Human TGF-1, a Bone Morphogenetic Protein-1, a Recombinant Human BMP-2, an Osteogenic growth peptide, a Recombinant Human Growth Hormone, a Basic fibroblast Growth Factor, or a Hepatocyte Growth Factor.
  • 25. The method of claim 18 wherein said suture anchor comprises a biocompatible material wherein said biocompatible material includes at least one of a stainless steel, a titanium, a polymer, a bone, or an absorbable.
  • 26. The method of claim 25 wherein said polymer includes at least one of a polyester, a nylon, a poly lactic acid (PLA), a poly-L lactic acid (PLLA), or a poly galactic acid (PGA).
  • 27. The method of claim 18 wherein said suitable coating comprises at least one site specific drug including a Tobramycin, a Gentamicin, a Cefazolin, a Vancomycin, a Cephalothin, an Oxacillin-nafcillin, a Ceftriaxone, a Cefuroxime, an Unspecified cephalosporin, a Bacitracin, an Erythromycin-colistin, or a Polymyxin B.
  • 28. The method of claim 18 wherein:said suture comprises braided filaments having interstices and said suitable coating covers a predetermined portion of said interstices of said suture.
  • 29. The method of claim 28 further comprising impregnating said suitable coating into at least one of said suture anchor or said suture.
  • 30. The method of claim 18 wherein coating the suture anchor includes impregnating the suitable coating into the suture anchor.
Parent Case Info

This application is a Continuation-In-Part of and claims priority to U.S. Provisional Application Ser. No. 60/129,675, filed Apr. 16, 1999.

US Referenced Citations (228)
Number Name Date Kind
1105105 Sherman Jul 1914 A
2100570 Rohmer Saleh Nov 1937 A
2143086 Pleister Jan 1939 A
2242003 Lorenzo May 1941 A
2381050 Hardinge Aug 1945 A
2397545 Hardinge Apr 1946 A
2414882 Longfellow Jan 1947 A
2570465 Lundholm Oct 1951 A
2685877 Dobelle Aug 1954 A
3003155 Mielzynski et al. Oct 1961 A
3123077 Alcamo Mar 1964 A
3273442 Launay Sep 1966 A
3289290 Sandor Dec 1966 A
3312139 Di Cristina Apr 1967 A
3316796 Young May 1967 A
3405595 Peterson Oct 1968 A
3463209 Podolsky Aug 1969 A
3499222 Linkow et al. Mar 1970 A
3566739 Lebar Mar 1971 A
3708883 Flander Jan 1973 A
3716058 Tanner, Jr. Feb 1973 A
3888144 Parsons Jun 1975 A
3910281 Kletschka et al. Oct 1975 A
3976079 Samuels et al. Aug 1976 A
3987797 Stephenson Oct 1976 A
4011602 Rybicki et al. Mar 1977 A
4013071 Rosenberg Mar 1977 A
4175555 Herbert Nov 1979 A
4275717 Bolesky Jun 1981 A
4409974 Freedland Oct 1983 A
4463753 Gustilo Aug 1984 A
4469101 Coleman et al. Sep 1984 A
4476590 Scales et al. Oct 1984 A
4484570 Sutter et al. Nov 1984 A
4493323 Albright et al. Jan 1985 A
4532926 O'Holla Aug 1985 A
4537185 Stednitz Aug 1985 A
4548202 Duncan Oct 1985 A
4573844 Smith Mar 1986 A
4632100 Somers et al. Dec 1986 A
4636121 Miller Jan 1987 A
4662886 Moorse et al. May 1987 A
4708132 Silvestrini Nov 1987 A
4711232 Fischer et al. Dec 1987 A
4711234 Vives et al. Dec 1987 A
4716893 Fischer et al. Jan 1988 A
4744793 Parr et al. May 1988 A
4759765 Van Kampen Jul 1988 A
4772286 Goble et al. Sep 1988 A
4776328 Frey et al. Oct 1988 A
4776329 Treharne Oct 1988 A
4776330 Chapman et al. Oct 1988 A
4851005 Hunt et al. Jul 1989 A
4870957 Goble et al. Oct 1989 A
4871289 Choiniere Oct 1989 A
4873976 Schreiber Oct 1989 A
4884572 Bays et al. Dec 1989 A
4895148 Bays et al. Jan 1990 A
4898156 Gatturna et al. Feb 1990 A
4899743 Nicholson et al. Feb 1990 A
4917554 Bronn Apr 1990 A
4924865 Bays et al. May 1990 A
4927421 Goble et al. May 1990 A
4940467 Tronzo Jul 1990 A
4946468 Li Aug 1990 A
4950270 Bowman et al. Aug 1990 A
4968315 Gatturna Nov 1990 A
4976715 Bays et al. Dec 1990 A
4988351 Paulos et al. Jan 1991 A
4997433 Goble et al. Mar 1991 A
5002550 Li Mar 1991 A
5013316 Goble et al. May 1991 A
5037422 Hayhurst et al. Aug 1991 A
5041129 Hayhurst et al. Aug 1991 A
5046513 Gatturna et al. Sep 1991 A
5061181 Niznick Oct 1991 A
5067956 Buford, III et al. Nov 1991 A
5084050 Draenert Jan 1992 A
5098434 Serbousek Mar 1992 A
5100417 Cerier et al. Mar 1992 A
5102421 Anspach, Jr. Apr 1992 A
5129906 Ross et al. Jul 1992 A
5141520 Goble et al. Aug 1992 A
5152765 Ross et al. Oct 1992 A
5156616 Meadows et al. Oct 1992 A
D331626 Hayhurst et al. Dec 1992 S
5176682 Chow Jan 1993 A
5192303 Gatturna et al. Mar 1993 A
5203787 Noblitt et al. Apr 1993 A
5207679 Li May 1993 A
5209753 Biedermann et al. May 1993 A
5211647 Schmieding May 1993 A
RE34293 Goble et al. Jun 1993 E
5217486 Rice et al. Jun 1993 A
5224946 Hayhurst et al. Jul 1993 A
5234430 Huebner Aug 1993 A
5246441 Ross et al. Sep 1993 A
5258016 DiPoto et al. Nov 1993 A
5268001 Nicholson et al. Dec 1993 A
5282832 Toso et al. Feb 1994 A
5306290 Martins et al. Apr 1994 A
5312438 Johnson May 1994 A
5324308 Pierce Jun 1994 A
5326205 Anspach, Jr. et al. Jul 1994 A
5336225 Zang Aug 1994 A
5336240 Metzler et al. Aug 1994 A
5354298 Lee et al. Oct 1994 A
5354299 Coleman Oct 1994 A
5356413 Martins et al. Oct 1994 A
5358511 Gatturna et al. Oct 1994 A
5370662 Stone et al. Dec 1994 A
5372599 Martins Dec 1994 A
5372604 Trott Dec 1994 A
5383878 Roger et al. Jan 1995 A
RE34871 McGuire et al. Mar 1995 E
5411522 Trott May 1995 A
5411523 Goble May 1995 A
5417691 Hayhurst May 1995 A
5417712 Whittaker et al. May 1995 A
5423819 Small et al. Jun 1995 A
5425733 Schmieding Jun 1995 A
5425767 Steininger Jun 1995 A
5441502 Bartlett Aug 1995 A
5443482 Stone et al. Aug 1995 A
5443509 Boucher et al. Aug 1995 A
5454811 Huebner Oct 1995 A
5456685 Huebner Oct 1995 A
5458601 Young, Jr. et al. Oct 1995 A
5464425 Skiba Nov 1995 A
5464427 Curtis et al. Nov 1995 A
5466243 Schmieding et al. Nov 1995 A
5470334 Ross et al. Nov 1995 A
5472452 Trott Dec 1995 A
5480403 Lee et al. Jan 1996 A
5486197 Le et al. Jan 1996 A
5489210 Hanosh Feb 1996 A
5496326 Johnson Mar 1996 A
5500001 Trott Mar 1996 A
5501683 Trott Mar 1996 A
5501695 Anspach, Jr. et al. Mar 1996 A
5501696 Trott Mar 1996 A
5505735 Li Apr 1996 A
5520696 Wenstrom, Jr. May 1996 A
5522843 Zang Jun 1996 A
5522845 Wenstrom, Jr. Jun 1996 A
5545178 Kensey et al. Aug 1996 A
5545180 Le et al. Aug 1996 A
5554171 Gatturna et al. Sep 1996 A
5571104 Li Nov 1996 A
5571139 Jenkins, Jr. Nov 1996 A
5573548 Nazre et al. Nov 1996 A
5578044 Gordon et al. Nov 1996 A
5578057 Wenstrom, Jr. Nov 1996 A
5584835 Greenfield Dec 1996 A
5584836 Ballintyn et al. Dec 1996 A
5591207 Coleman Jan 1997 A
5601557 Hayhurst Feb 1997 A
5607432 Fucci Mar 1997 A
5626613 Schmieding May 1997 A
5630824 Hart May 1997 A
5632748 Beck, Jr. et al. May 1997 A
5643320 Lower et al. Jul 1997 A
5643321 McDevitt Jul 1997 A
5645589 Li Jul 1997 A
5647874 Hayhurst Jul 1997 A
5649963 McDevitt Jul 1997 A
5662654 Thompson Sep 1997 A
5662658 Wenstrom, Jr. Sep 1997 A
5662683 Kay Sep 1997 A
5669935 Rosenman et al. Sep 1997 A
5683401 Schmieding et al. Nov 1997 A
5683418 Luscombe et al. Nov 1997 A
5690649 Li Nov 1997 A
5690676 DiPoto et al. Nov 1997 A
5690677 Schmieding et al. Nov 1997 A
5697950 Fucci et al. Dec 1997 A
5707395 Li Jan 1998 A
5715942 Li et al. Feb 1998 A
5720766 Zang et al. Feb 1998 A
5725529 Nicholson et al. Mar 1998 A
5725557 Gatturna et al. Mar 1998 A
5728116 Rosenman Mar 1998 A
5741300 Li Apr 1998 A
5743914 Skiba Apr 1998 A
5782864 Lizardi Jul 1998 A
5782866 Wenstrom, Jr. Jul 1998 A
5797963 McDevitt Aug 1998 A
5800447 Wenstrom, Jr. Sep 1998 A
5814071 McDevitt et al. Sep 1998 A
5827291 Fucci et al. Oct 1998 A
5851219 Goble et al. Dec 1998 A
5860978 McDevitt et al. Jan 1999 A
5871490 Schulze et al. Feb 1999 A
5885294 Pedlick et al. Mar 1999 A
5893856 Jacob et al. Apr 1999 A
5895396 Day et al. Apr 1999 A
5895425 Grafton et al. Apr 1999 A
5899938 Sklar et al. May 1999 A
5904696 Rosenman May 1999 A
5904704 Goble et al. May 1999 A
5911721 Nicholson et al. Jun 1999 A
RE36289 Le et al. Aug 1999 E
5931840 Goble et al. Aug 1999 A
5935134 Pedlick et al. Aug 1999 A
5951997 Bezwada et al. Sep 1999 A
5961538 Pedlick et al. Oct 1999 A
5964783 Grafton et al. Oct 1999 A
5968044 Nicholson et al. Oct 1999 A
5971987 Huxel et al. Oct 1999 A
5984927 Wenstrom, Jr. et al. Nov 1999 A
5993477 Vaitekunas et al. Nov 1999 A
6007566 Wenstrom, Jr. Dec 1999 A
6019768 Wenstrom, Jr. et al. Feb 2000 A
6027523 Schmieding Feb 2000 A
6036701 Rosenman Mar 2000 A
6045573 Wenstrom, Jr. et al. Apr 2000 A
6056778 Grafton et al. May 2000 A
6074395 Trott et al. Jun 2000 A
6080184 Peters et al. Jun 2000 A
6086591 Bojarski Jul 2000 A
6096060 Fitts et al. Aug 2000 A
6099568 Simonian et al. Aug 2000 A
6117162 Schmieding et al. Sep 2000 A
6139565 Stone et al. Oct 2000 A
6146387 Trott et al. Nov 2000 A
6146406 Shluzas et al. Nov 2000 A
6179840 Bowman Jan 2001 B1
6214031 Schmieding et al. Apr 2001 B1
Foreign Referenced Citations (27)
Number Date Country
0 232 049 Aug 1987 EP
0 241 240 Oct 1987 EP
0 260 970 Mar 1988 EP
0 270 704 Jun 1988 EP
0 340 159 Nov 1989 EP
0 374 088 Jun 1990 EP
0 409 364 Jan 1991 EP
0 451 932 Oct 1991 EP
0 464 480 Aug 1992 EP
0 502 509 Sep 1992 EP
0 528 573 Feb 1993 EP
0 574 707 Dec 1993 EP
0 615 732 Jul 1994 EP
0 674 880 Oct 1995 EP
2 622 430 May 1989 FR
WO 8503857 Sep 1985 WO
WO 8603666 Jul 1986 WO
WO 8701270 Mar 1987 WO
WO 8809157 Dec 1988 WO
WO 8909030 Oct 1989 WO
WO 8910096 Nov 1989 WO
WO 9204874 Apr 1992 WO
WO 9515726 Jun 1995 WO
WO 9525469 Sep 1995 WO
WO 9527449 Oct 1995 WO
WO 9529637 Nov 1995 WO
WO 9730639 Aug 1997 WO
Non-Patent Literature Citations (49)
Entry
“Anterior Cruciate Ligament Allograft Transplatation Long-term Function, Histology, Revascularization, and Operative Technique,” Pantelis K. Nikolaou, M.D., Anthony V. Seaber, Richard R. Glisson, Beth M. Ribbeck, MS, and Frank H. Bassett III, M.D., American Journal of Sports Medicine, 14(5):348-360 (1986).
“Vascularized Patellar Tendon Graft with Rigid Internal Fixation for Anterior Cruciate Ligament Insufficiency,” Kenneth L. Lambert, MD, Clinical Orthopedics and Related Research, 172, Jan.-Feb. (1983).
Advertisement, Innovasive Devices Brochures, Feb. 1995.
Rushton, D.N., Brindley, G.S., Polkey, C.E. and Browning, G.V., “Implant Infections and Antibiotic-Impregnated Silicone Rubber Coating,” Journal of Neurology, Neurosurgery, and Psychiatry, (1989), pp. 223-229.
Fish, Douglas N., Hoffman, Heather M. and Danziger, Larry H., “Antibiotic-Impregnated Cement Use in U.S. Hospitals,” American Journal Hospital Pharmacists, vol. 49, (Oct. 1992), pp. 2469-2474.
Henry, M.D., Stephen L., Ostermann, M.D., Peter A.W. and Seligson, M.D., David, “The Antibiotic Bead Pouch Technique: The Management of Severe Compound Fractures,” Clinical Orthopaedics and Related Research, No. 295, (1993), pp. 54-62.
Gref, Ruxandra, Minamitake, Yoshiharu, Peracchia, Maria Teresa, Trubetskoy, Vladimir, Torchilin, Vladimir and Langer, Robert, “Biodegradable Long-Circulating Polymeric Nanospheres,” Science, vol. 263 (Mar. 18, 1994), pp. 1600-1603.
Barber, M.D., F. Alan, Herber, Ph.D., Morley A. and Click, P.A.-C., James N., “The Ultimate Strength of Suture Anchors,” Arthroscopy: The Journal of Arthoroscopic and Related Surgery, vol. 11, No. 1 (Feb. 1995), pp. 21-28.
Product List For American Cyanamid Co., pp. ii-v—“Absorbable Sutures,” American Cyanamid Co., p. ii—“Nonabsorbable Sutures,” American Cyanamid Co., pp. iii-v.
Ticker, M.D., Jonathan B., Lippe, M.D., Robert J., Barkin, M.D., Douglas E. and Carroll, M.D., Michael P., “Infected Suture Anchors in the Shoulder,” Arthroscopy: The Journal of Arthoroscopic and Related Surgery, vol. 12, No. 5 (Oct. 1996), pp. 613-615.
Radomsky, M., Merck, A., Gonslaves, M., Anudokem, G. and Poser J., “Basic Fibroblast Growth Factor in a Hyaluronic Acid Gel Stimulates Intramebranous Bone Formation,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 510.
Wakitani, S., Imoto, K., Murata, N., Oonishi, H., Kimura, T., Tomita, T., Ochi, T., Matsumoto, K. and Nakamura, T., “The Effect of Hepatocyte Growth Factor on Repair of Rabbit Articular Cartilage Defect,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 512.
Sperling, J.W., Fitzsimmons, J.S. and O'Driscoll, S.W., “Growth Hormone Enhancement of Chondrogenesis in Periosteal Explants,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 513.
Reynolds, S.D., Reyolds, P.R., Moylan, P.E. and Anderson, H.C., “Identification of Bone Morphogenetic Protein-1 (BMP-1) in Osteoinductive SAOS-2 Cell Products and Induced Heteroptopic Bone,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 525.
Brager, M.A., Patterson, M.J., Gibson, J.S., Connolly, J.F. and Nevo, Z., “The Effect of Osteogenic Growth Peptide Injections on Fracture Healing in Rats,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 527.
Lind, M., Overgaard, S., Glenup, M., Bunger, C. , and Soballe, K., “Transforming Growth Factor-B1 Accelerates Bone Cell Repair Activity in a Gap Around Ceramic Coated Implants in Dogs,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 528.
Kim, H.D., Smith, J.G. and Valentini, R.F., “Bone Morphogenetic Protein-2 Induction of Pluripotent C3H10T1/2 Cells in Porous PLLA Scaffolds,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 546.
Santos, E.M., Ducheyne, P., Radin, S. and Shapiro, I.M., “The Effect of Bioactive Xerogel Glass With and Without Bone Morphogenetic Protien on Stromal Marrow Cell Function,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 547.
Hanlon, J., Yaeger, P., McPherson, J., Tubo, R. and Binette, F., “Redifferentiation of Passaged Human Articular Chondrocytes in Type-I Collagen Sponges is Enhanced with Transforming Growth Factor-B Supplementation,” 43rd Annual Meeting, Orthopaedic Research Society, (Feb. 1997, S.F., CA), p. 551.
Barber, M.D., F. Alan, Cherf, M.D., MPH, John M. and McCarty, CSCS, AT, C, Timothy M., “Suture Anchors Product Information Guide,” Orthopedic Special Edition, (Winter/Spring 1997), pp. 1-8.
Gupta, Bhupender S., “Medical Textile Structures: An Overview,” Medical Plastics and Biomaterials Magazine (MPB Archive), (Jan. 1998) also available on http://www.devicelink.com/mpb/archive/98/01/001.html.
Tunney, Michael M., Ramage, Gordon, Patrick, Sheila, Nixon, James R., Murphy, Philip G. and Gorman, Sean P., “Antimicrobial Susceptibility of Bacteria Isolated From Orthopedic Implants Following Revision Hip Surgery,” Antimicrobial Agents Chemotherapy, vol. 42, No. 11, (Nov. 1998), pp. 3002-3005 also available on http://aac.asm.org/cgi/content/full/42/11/3002.
Murata, M., Huang, B.Z., Shibata, T., Imai, S., Nagai, N. and Arisue, M., “Bone Augmentation by Recombinant Human BMP-2 and Collagen on Adult Rat Parietal Bone,” International Journal of Oral and-Maxillofacial Surgery, vol. 28, No. 3 (Jun. 1999), pp. 232-237.
Carnes, Jr., D.L., De La Fontaine, J., Cochran, D.L., Mellonig, J.T., Keogh, B., Harris, S.E., Chosh-Choudhury, N., Dean, D.D., Boyan, B.D. and Schwartz, Z., “Evaluation of 2 Novel Approaches For Assessing the Ability of Demineralized Freeze-Dired Boe Allograft to Induce New Bone Formation,” Journal of Periodontology, vol. 70, No. 4, (Apr. 1999), pp. 353-363.
Kleef, J., Maruyama, H. Ishiwata, T., Sawhney, H., Friess, H., Buchler, M.W. and Korc, M., “Bone Morphogenetic Protein 2 Exerts Diverse Effects on Cell Growth in Vitro and is Expressed in Human Pancreatic Cancer in Vivo,” Gastroenterology, vol. 116, No. 5, (May 1999), pp. 1202-1206.
Ono, I., Tateshita, T., Takita, H. and Kuboki, Y., “Promotion of the Osteogenetic Activity of Recombinant Human Bone Morphogenetic Protein by Basic Fibroblast Growth Factor,” Journal of Carniofacial Surgery, vol. 7, No. 6 (Nov. 1996), pp. 418-425.
Scheufler, C., Sebald, W. and Hulsemeyer, “Crystal Structure o f Human Bone Morphogenetic Protien-2 at 2.7 A Resolution,” Journal of Molecular Biology, vol. 287, No. 1, (Mar. 1999), pp. 103-115.
Schwartz, Z., Somers, A., Mellonig, J.T., Carnes, Jr., D.L., Wozney, J.M., Dean, D.D., Cochran, D.L. and Boyan, B.D., “Addition of Human Recombinant Bone Morphogenetic Protein-2 to Inactive Commercial Human Demineralized Freeze-Dried Bone Allograft Makes an Effective Composite Bone Inductive Implant Materials,” Journal of Periodontology, vol. 69, No. 12, (Dec. 1998), pp. 1337-1345.
DeGroot, J., “Carriers That Concentrate Native Bone Morphogenetic Protien in Vivo,” Tissue Engineering, vol. 4, No. 4, (Winter 1998), pp. 337-341.
Whang, K., Tsai, D.C., Nam, E.K., Aitken, M., Sprague, S.M., Patel, P.K. and Healy, K.E., “Ectopic Bone Formation Via rhBMP-2 Delivery From Porous Bioabsorbable Polymer Scaffolds,” Journal of Biomedical Materials Research, vol. 42, No. 4, (Dec. 1998), pp. 491-499.
Lind, M., “Growth Factor Stimulation of Bone Healing. Effects on Osteoblasts, Osteomies, and Implants Fixation,” Acta Orthopaedica Scandinavica Supplementum, vol. 283, (Oct. 1998), pp. 2-37.
Illi, O.E., and Feldmann, C.P., “Stimulation of Fracture Healing by Local Application of Humoral Factors Integrated in Biodegradable Implants,” European Journal of Pediatric Surgery, vol. 8, No. 4 (Aug. 1998), pp. 251-255.
Si, S., Jin, Y. and Yang, L., “Induction of New Bone by Ceramic Bovine Bone With Recombinant Human Bone Morphogenetic Protein 2 and Transforming Growth Factor Beta,” International Journal of Oral and Maxillofacial Surgery, vol. 27, No. 4 (Aug. 1998), pp. 310-314.
Yamamoto, M., Tabata, Y. and Ikada, Y., “Ectopic Bone Formation Induced by Biodegradable Hydrogels Incorporating Bone Morphogenetic Protein,” Journal of Biomaterials Science, Polymer Edition, vol. 9, No. 5, (1998), pp. 439-458.
Soda, H., Raymond, E., Sharma, S., Lawrence, R., Cerna, C., Gomez, L., Timony, G.A., Von Hoff, D.D., and Izbicka, E., “Antiproliferation Effects of Recombinant Human Bone Morphogenetic Protein-2 on Human Tumor Colony-Forming Units,” Anti-Cancer Drugs, vol. 9, No. 4, (Apr. 1998), pp. 327-331.
Schwartz, Z., Somers, A., Mellonig, J.T., Carnes, Jr., D.L., Dean, D.D., Cochran, D.L. and Boyan, B.D., “Ability of Commerical Demineralized Freeze-Dried Bone Allograft to Induce New Bone Formation is Dependent on Donor Age But Not Gender,” Journal of Periodontology, vol. 69, No. 4, (Apr. 1998), pp. 470-478.
Rodgers, J.B., Vasconez, H.C., Wells, M.D., DeLuca, P.P., Faugere, M.C., Fink, B.F. and Hamilton, D., “Two Lyophilized Polymer Matrix Recombinant Human Bone Morphogenetic Protein-2 Carriers in Rabbit Calvarial Defects,” Journal of Craniofacial Surgery, vol. 9, No. 2, (Mar. 1998), pp. 147-153.
Omura, S., Mizuki, N., Kawabe, R., Ota, S., Kobayashi, S. and Fujita, K., “A Carrier For Clinical Use of Recombinant Human BMP-2: Dehydrothermally Cross-Linked Composite of Fibrillar and Denatured Atelocollagen Sponge,” International Journal of Oral and Maxillofacial Surgery, vol. 27, No. 2, (Apr. 1998), pp. 129-134.
von Fraunhofer, J.A., Storey, R.S., Stone, I.K. and Masterson, B.J., “Tensile Strength of Suture Materials,” Journal of Biomedical Materials Research, vol. 19, No. 5, (May-Jun. 1985), pp. 595-600.
Damien, C.J. and Parsons, J.R., “Bone Graft and Bone Substitutes: A Review of Current Technology and Applications,” Journal of Applied Biomaterials, vol. 2, No. 3, (Fall 1991), pp. 187-208.
Toriumi, D.M., East, C.A., and Larrabee, W.F., “Osteoinductive Biomateiials For Medical Implantation,” Journal of Long-Term Effects of Medical Implants, vol. 1, (1991), pp. 53-77.
Paralkar, V.M., Hammonds, R.G. and Reddi, A.H., “Identification and Charachterization of Cellular Binding Proteins (Receptors) For Recombinant Human Bone Morphogenetic Protein 2B, and Initiator of Bone Differentiation Cascade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, No. 8, (Apr. 15, 1991), pp. 3397-3401.
Metz, S.A., von Fraunhofer, J.A. and Masterson, B.J., “Stress Relaxation of Organic Suture Materials,” Biomaterials, vol. 11, No. 3, (Apr. 1990), pp. 197-199.
Wang, E.A., “Bone Morphogenetic Proteins (BMPs): Therapeutic Potential in Healing Bony Defects,” Trends in Biotechnology, vol. 11, No. 9, (Sep. 1993), pp. 379-383.
Niederwanger, M. and Urist, M.R., “Demineralized Bone Matrix Supplied by Bone Banks For a Carrier of Recombinant Human Bone Morphogenetic Protein (rhBMP-2): a Substitute For Autogenetic Bone Grafts,” Journal of Oral Implantology, vol. 22, Nos. 3-4, (1996), pp. 210-215.
Zellin, G. and Linde, A., “Importance of Delivery Systems For Growth-Stimulatory Factors in Combination With Osteopromotive Membranes. An Experimental Study Using rhBMP-2 in Rat Mandibular Defects,” Journal of Biomedical Materials Research, vol. 35, No. 2, (May 1997), pp. 181-190.
Tsuruga, E., Takita, H., Itoh, H., Wakisaka, Y. and Kuboki, Y., “Pore Size of Porous Hydroxyapatite as the Cell-Substratum Controls BMP-Induced Osteogenesis,” Journal of Biochemistry, vol. 121, No. 2, (Feb. 1997), pp. 217-324.
Harakas, N.K., “Demineralized Bone-Matrix-Induced Osteogenesis,” Clinical Orthopaeidics and Related Research, vol. 188, (Sep. 1984), pp. 239-251.
Johnson, E.E., Urist, M.R., and Finerman, G.A., “Bone Morphogenetic Protein Augmentation Grafting of Resistant Femoral Nonunions. A Preliminary Report,” Clinical Orthopaedica and Related Research, vol. 230, (May 1988), pp. 257-265.
Provisional Applications (1)
Number Date Country
60/129675 Apr 1999 US